Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro

European Journal of Nuclear Medicine

Volumn 25, Issue 7, 1998, Pages 788-792

  Dearling, Jason L J ^a   Lewis, Jason S ^a   Mullen, Gregory E D ^a   Rae, Michael T ^a   Zweit, Jamal ^b,d   Blower, Philip J ^a,c  

^a UNIVERSITY OF KENT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Copper 64; Hypoxia; Positron emission tomography

Indexed keywords

COPPER 64; LIGAND; OXYGEN; RADIOPHARMACEUTICAL AGENT; SALICYLALDIMINE; SULFUR; THIOSEMICARBAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CENTRIFUGATION; CHO CELL; CONTROLLED STUDY; DONOR; DRUG TARGETING; ELECTRON; FEMALE; HYPOXIA; HYPOXIC CELL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOTHERAPY;

ANIMALS; CELL HYPOXIA; CHO CELLS; COPPER RADIOISOTOPES; CRICETINAE; DRUG DESIGN; OXYGEN CONSUMPTION; RADIOPHARMACEUTICALS; SALICYLAMIDES; THIOSEMICARBAZONES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031869326     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050283     Document Type: Article

References (10)

1. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-280.
2. Kapoor S, Gopinathan C. Calculations on high LET radiation tracks. J Radioanal Nucl Chem 1991; 150: 3-13.
3. Cook JR, Houston S, Barrington SF, Fogelmun I. Technetium-99m-labeled HL91 to identify tumour hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39: 99-103.
4. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957-980.
5. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-1160.
6. John EK, Bott AJ, Green MA. Preparation and biodistribution of copper-67 complexes with tetradentate Schiff-base ligands, J Pharm Sci 1994; 83: 587-590.
7. 64Ni targets for positron emission tomography. Appl Radiat Isot 1991; 42: 193-197.
8. Kallinowski F. The role of tumour hypoxia for the development of future treatment concepts for locally advanced cancer. Cancer J 1996; 9: 37-40.
9. Taniuchi H, Fujibayashi Y, Yonekura Y, Kinosi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med 1997; 38: 1130-1134.
10. Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med 1989; 30: 1843-1847.